IMM: Discontinuation of TACTI-004 caused impairment, but strong cash and positive clinical data support future prospectsQuartr·Aug 30 at 11:34 PMIMMP-0.05%RDY-0.50%
IMM: First-in-class immunotherapies efti and IMP761 advance in oncology and autoimmunityQuartr·Aug 20 at 10:54 PMIMMP-0.05%
02:19 ETImmutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMPprnewswire·Jun 8 at 06:20 AMIMMP-0.05%
02:40 ETIMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firmprnewswire·Jun 5 at 06:40 AMIMMP-0.05%
03:02 ETImmutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMPprnewswire·Jun 3 at 07:03 AMIMMP-0.05%
19:13 ETIMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuitprnewswire·May 29 at 11:13 PMIMMP-0.05%
03:55 ETIMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuitprnewswire·May 25 at 07:55 AMIMMP-0.05%
Immutep Gets FDA Boost For Lead Cancer Drug, Stock Doublesbenzinga_article·Apr 15 at 04:40 PMIMMP-0.05%
Immutep shares are trading higher after the FDA granted the company Orphan Drug Designation for for eftilagimod alfa for the treatment of Soft Tissue Sarcomabenzinga_article·Apr 15 at 12:05 PMIMMP-0.05%
Immutep Ends Key Lung Cancer Trial but Stresses Strength of PipelineTip Ranks·Apr 8 at 12:38 AMIMMP-0.05%
Imugene calls hybrid Extraordinary General Meeting with expanded online accessTip Ranks·Mar 22 at 11:24 PM
Immutep Discontinues Phase III Trial Of Eftilagimod Alfa In First-Line NSCLC; Stock Dropsrttnews·Mar 13 at 07:34 AMIMMP-0.05%
